Ipamorelin vs GHRP-2

Two agonists at the same receptor, separated by selectivity rather than target. Why the cleaner compound is not automatically the better research tool.

Same receptor, different behaviour

Both Ipamorelin and GHRP-2 are synthetic agonists at GHSR-1a, the ghrelin receptor. Neither acts at the GHRH receptor that CJC-1295 and Sermorelin target, so the comparison is genuinely like for like.

What separates them is what else they do. GHRP-2 is the more potent releaser of growth hormone, and it also produces measurable increases in cortisol, prolactin and ACTH. Ipamorelin was designed to reduce that cross-activity and largely succeeds, at the cost of releasing less growth hormone. Hexarelin sits further along the same axis: more potent again, and less selective again.

Where they differ

Potency. GHRP-2 produces a larger GH response than Ipamorelin at comparable research concentrations.
Cortisol and ACTH. Measurable with GHRP-2; minimal with Ipamorelin at the concentrations usually studied.
Prolactin. Same pattern — a known confounder with GHRP-2, largely absent with Ipamorelin.
Appetite signalling. GHRP-2 shows more ghrelin-like appetite activity, which is either a confounder or the subject of the study depending on the design.
Structure. Ipamorelin is a pentapeptide containing two D-amino acids and a C-terminal amide; GHRP-2 is a hexapeptide of different composition.
Desensitisation. More pronounced with the more potent agonists of this class, which matters in repeated-exposure designs.

Which suits which question

Where the objective is to attribute an observation to growth hormone signalling specifically, Ipamorelin is the better instrument. Cortisol affects metabolic, immune and behavioural endpoints, and a compound that raises it alongside GH makes clean attribution impossible without additional controls.

Where the objective is maximum release — a saturating stimulus for a pituitary response assay, for instance — or where the broader ghrelin-receptor profile is itself the subject, GHRP-2 is the appropriate choice and its lack of selectivity is not a defect. Hexarelin extends that logic further still.

Both are commonly paired with a GHRH analogue, since the two receptor families are independent; the CJC-1295 / Ipamorelin preparation is the packaged version of that pairing.

How both are supplied

Ipamorelin and GHRP-2 Acetate are both lyophilised in sealed vials, each batch specified at 99% purity or better by HPLC with identity confirmed by mass spectrometry and released against a batch-matched Certificate of Analysis. The process is on the lab testing page. Both sit in the growth and recovery group alongside MK-677, the orally active small-molecule agonist at the same receptor.

Research use only

Both compounds are laboratory reference materials. Neither is a medicine, a supplement, or for human or veterinary use, and no dosing guidance or administration protocol is provided for either. The full terms are in the research use policy. Every guide is indexed in the research library.